Member Info for mazik

Touched 22p now :-)

There is no ramper here as N4P has decided to go up on its own merit :-)

Is it over 21p? That morning dose has worked :-)

Dose of Viagra needed..

Does of Viagra needed :-)

Buyer bought a block of approx 800k before 9 am...someone snapping

Market is consolidating betting firms with presence in US....GAN is flourishing, we have a multibagger opportunity..imo

Very few shares around any buying will catapult over double figures IMO

Buyout on the cards IMO, well a topup will do me fine :-)

Quote from Matric CEO "Supreme Court decision signals a sea change in the U.S and believe that its multi-device approach gives our state-of-the-art horse racing and sports betting counterparts a price and functionality advantage over legacy based competitors in both the retail and iGaming spaces." This has given huge potential for Webis too..IMO

Volcano my apology well we are here to make money, my opinion its oversold as it has been 100% up in the last one week and its invetible for retrace.. Have a good evening..tomorrow is another day for Steak..GLA

All possible very strong performance

Woodford, Schroders and new holders Nordic HealthInvest are on board too...GLA

Buyout will not be cheap..expecting 30p plus IMO

Looks like u have nothing better to do than deramp, sad human...volcano sums it up :-)

MMs play while the market is steady...they try to rinse and repeat but we have base at 19p..IMO

Definately there is a deal being mulled, a massive volume in the last few days IMO

My 76k buy showing as sold :-) There is more to this speculation ...someone is interested IMO

Morning PK ..Patience is the key here, base is formed ...looking forward for coming weeks for news.

Patience is the key, its a life changing opportunity with a great team . IMO "Dr Chris Blackwell, B.Sc, Ph.D. served as CEO of Vectura Group Plc from February 2004 to June 2015, taking the company through its initial IPO to a valuation of over $1 billion. Chris presided over a period of significant growth including deal-making (including a $375m out-licensing agreement with Novartis, Europe's largest biotech deal of 2005), fund-raising, M&A and corporate development that transformed Vectura's capabilities from research led technology development to commercially driven pharmaceutical development. Chris' track record and experience will guide Nuformix through its next stage of growth. "